Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann H Partridge

Showing results (231-240 of 363) with videos related to

Pageof 37
Sort By:
Future Oncology (London, England)|June 26, 2024
OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancerSara M Tolaney, Angela DeMichele, Toshimi Takano, et al.
NPJ Breast Cancer|July 28, 2021
Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancerPhilip D Poorvu, Jiani Hu, Yue Zheng, et al.
JCO Precision Oncology|December 7, 2023
Endometrial Cancer Risk Among Germline <i>BRCA1</i>/<i>2</i> Pathogenic Variant Carriers: Review of Our Current Understanding and Next StepsKimia Sorouri, Filipa Lynce, Colleen M Feltmate, et al.
Breast Cancer Research and Treatment|November 26, 2020
Tumor phenotype and concordance in synchronous bilateral breast cancer in young womenLinda M Pak, Rachel Gaither, Shoshana M Rosenberg, et al.
Breast (Edinburgh, Scotland)|March 12, 2017
Fertility concerns among breast cancer patients in MexicoCynthia Villarreal-Garza, Bertha Alejandra Martinez-Cannon, Alejandra Platas, et al.
Cancer Discovery|December 16, 2016
Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast CancersSarah Naomi Olsen, Ania Wronski, Zafira Castaño, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2- Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7Aleix Prat, Nadia Solovieff, Fabrice André, et al.
Cancer|March 6, 2023
The influence of anatomic stage and receptor status on first recurrence for breast cancer within 5 years (AFT-01)Heather B Neuman, Jessica R Schumacher, Stephen B Edge, et al.
JAMA Oncology|April 11, 2024
Second Primary Breast Cancer in Young Breast Cancer SurvivorsKristen D Brantley, Shoshana M Rosenberg, Laura C Collins, et al.
Breast (Edinburgh, Scotland)|April 29, 2014
First international consensus guidelines for breast cancer in young women (BCY1)Ann H Partridge, Olivia Pagani, Omalkhair Abulkhair, et al.
Pageof 37

Showing results (231-240 of 363) with videos related to

Sort By:
Pageof 37
Future Oncology (London, England)|June 26, 2024
OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancerSara M Tolaney, Angela DeMichele, Toshimi Takano, et al.
NPJ Breast Cancer|July 28, 2021
Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancerPhilip D Poorvu, Jiani Hu, Yue Zheng, et al.
JCO Precision Oncology|December 7, 2023
Endometrial Cancer Risk Among Germline <i>BRCA1</i>/<i>2</i> Pathogenic Variant Carriers: Review of Our Current Understanding and Next StepsKimia Sorouri, Filipa Lynce, Colleen M Feltmate, et al.
Breast Cancer Research and Treatment|November 26, 2020
Tumor phenotype and concordance in synchronous bilateral breast cancer in young womenLinda M Pak, Rachel Gaither, Shoshana M Rosenberg, et al.
Breast (Edinburgh, Scotland)|March 12, 2017
Fertility concerns among breast cancer patients in MexicoCynthia Villarreal-Garza, Bertha Alejandra Martinez-Cannon, Alejandra Platas, et al.
Cancer Discovery|December 16, 2016
Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast CancersSarah Naomi Olsen, Ania Wronski, Zafira Castaño, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2023
Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2- Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7Aleix Prat, Nadia Solovieff, Fabrice André, et al.
Cancer|March 6, 2023
The influence of anatomic stage and receptor status on first recurrence for breast cancer within 5 years (AFT-01)Heather B Neuman, Jessica R Schumacher, Stephen B Edge, et al.
JAMA Oncology|April 11, 2024
Second Primary Breast Cancer in Young Breast Cancer SurvivorsKristen D Brantley, Shoshana M Rosenberg, Laura C Collins, et al.
Breast (Edinburgh, Scotland)|April 29, 2014
First international consensus guidelines for breast cancer in young women (BCY1)Ann H Partridge, Olivia Pagani, Omalkhair Abulkhair, et al.
Pageof 37